Akarna Therapeutics is a privately held biopharmaceutical company developing novel small molecule therapeutics that target inflammatory and fibrotic diseases for which there is no approved treatment. Akarna's lead program is a potential best-in-class FXR agonist for the treatment of non-alcoholic steatohepatitis (NASH). Akarna's lead candidate is currently in preclinical, IND-enabling toxicology and safety pharmacology studies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/16/16 | $15,000,000 | Series B |
Forbion Capital Partners New Science Ventures Third Point Ventures | undisclosed |
